Home Cart Sign in  
Chemical Structure| 2097416-76-5 Chemical Structure| 2097416-76-5

Structure of Tizaterkib
CAS No.: 2097416-76-5

Chemical Structure| 2097416-76-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AZD0364 is an ERK1 and​/or ERK2 kinase for the treatment of cancer.

Synonyms: AZD0364; ATG-017

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tizaterkib

CAS No. :2097416-76-5
Formula : C24H24F2N8O2
M.W : 494.50
SMILES Code : O=C1C2=NC(C3=NC(NC4=CC=NN4C)=NC=C3C)=CN2C[C@H](COC)N1CC5=CC=C(F)C(F)=C5
Synonyms :
AZD0364; ATG-017
MDL No. :MFCD31631580
InChI Key :HVIGNZUDBVLTLU-MRXNPFEDSA-N
Pubchem ID :129116690

Safety of Tizaterkib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tizaterkib

MAPK

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Noise-induced hearing loss model Oral 0.1, 0.5, 5, 25 mg/kg Twice daily for 3 days Tizaterkib, when administered starting 24 hours after noise exposure, significantly reduced hearing loss in mice, protected against cochlear synaptopathy, and reduced immune cell infiltration in the cochlea. PMC10614960
Mice Noise-induced hearing loss model Oral 0.5 mg/kg/bw Twice daily for 3 days Alleviates noise-induced hearing loss, protects against cochlear synaptopathy, and reduces immune cell infiltration in the cochlea PMC11204379

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.02mL

0.40mL

0.20mL

10.11mL

2.02mL

1.01mL

20.22mL

4.04mL

2.02mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories